Sacituzumab Govitecan in Metastatic Breast Cancer

Affiliations

Comment

Shuvadeep Ganguly et al. N Engl J Med. 2021.

. 2021 Jul 15;385(3):e12.

doi: 10.1056/NEJMc2108478.

¹ All India Institute of Medical Sciences, New Delhi, India ajaygogia@gmail.com.

No abstract available

Comment in

Sacituzumab Govitecan in Metastatic Breast Cancer. Reply.
Bardia A, Hurvitz SA, Rugo HS. Bardia A, et al. N Engl J Med. 2021 Jul 15;385(3):e12. doi: 10.1056/NEJMc2108478. N Engl J Med. 2021. PMID: 34260848 No abstract available.

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.